Clarity secures IND from FDA for radiotracer for prostate cancer

2020 07 15 23 29 3710 Cancer Cells Prostate 400

Clarity Pharmaceuticals has secured investigational new drug approval (IND) from the U.S. Food and Drug Administration (FDA) to start a phase II clinical trial of a radiotracer for detecting cancer in asymptomatic patients.

The clearance is for Clarity's SAR-Bombesin agent, which detects prostate cancer in men who are prostate specific membrane antigen (PSMA)-negative, according to the firm. The trial, called Copper-64 SAR-Bombesin in Biochemical REcurrence of Prostate Cancer trial (SABRE), will include up to 50 PSMA-negative men who have biochemical recurrence of the disease after surgery or radiation.

Page 1 of 659
Next Page